An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies.
Parkinson Disease
Phase 2
A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
June 2014